The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, primarily through its Enhaze platform. This technology, based on the rHuPH20 ...

The Phase 1 trial is funded through Project NextGen, a U.S. government agency initiative to develop next-generation COVID-19 vaccines and therapeutics through public-private partnerships. The trial ...

When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts ...

A research team has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism. Click for my ARCT stock update.

Project NextGen is a $5 billion initiative aimed at developing the next generation of vaccines and therapeutics for COVID-19. Disclaimer: This is an AI-generated summary of a press release ...

"We are pleased with the approval of domestic manufacturing sites in Japan for KOSTAIVE ®," said Dr. Pad Chivukula, COO of Arcturus Therapeutics. "As a joint venture partner with ARCALIS ...